Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q3 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $175.8 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79